ADVENTRX Pharmaceuticals Inc. to Present at the 15th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference on February 12
Published: Feb 05, 2013
SAN DIEGO, Feb. 5, 2013 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the 15th Annual BIO CEO & Investor Conference on Tuesday, February 12, 2013 at 10:00a.m. Eastern time in the Duke of Windsor Salon at The Waldorf=Astoria Hotel in New York.
Interested parties can access a live audio webcast and slide presentation on the ADVENTRX Pharmaceuticals web site at www.adventrx.com. An archived presentation will be available on the web site for 30 days.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical company developing proprietary product candidates to treat various diseases and conditions. The Company's lead product candidate, ANX-188, has potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function, which is compromised in a wide range of serious and life-threatening diseases and conditions. The Company is recruiting subjects in EPIC, a randomized, double-blind, placebo-controlled phase 3 study of ANX-188 in patients with sickle cell disease. More information can be found on the Company's web site at www.adventrx.com.
SOURCE ADVENTRX Pharmaceuticals, Inc.